Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized usingex vivomyeloid-derived suppressor cells as a readout of therapeutic efficacy

Depletion of myeloid-derived suppressor cells during interleukin-12 immunogene therapy does not confer a survival advantage in experimental malignant glioma

(2014) B Thaci et al.   CANCER GENE THERAPY

Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice

(2014) J.-I. Youn et al.   JOURNAL OF IMMUNOLOGY

NK Cells Are Required for Dendritic Cell-Based Immunotherapy at the Time of Tumor Challenge

(2014) A. L. Bouwer et al.   JOURNAL OF IMMUNOLOGY

Trial Watch

(2014) Fernando Aranda et al.   OncoImmunology

DNA fusion vaccine designs to induce tumor-lytic CD8+ T-cell attack via the immunodominant cysteine-containing epitope of NY-ESO 1

(2013) Juan Campos-Perez et al.   INTERNATIONAL JOURNAL OF CANCER

Enhanced suppressive capacity of tumor-infiltrating myeloid-derived suppressor cells compared with their peripheral counterparts

(2013) Sarah K. Maenhout et al.   INTERNATIONAL JOURNAL OF CANCER

Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas

(2013) Sid P Kerkar et al.   MOLECULAR THERAPY

Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer

(2013) Je-In Youn et al.   NATURE IMMUNOLOGY

Assessing T-cell responses in anticancer immunotherapy

(2013) David Escors et al.   OncoImmunology

Role of non-classical MHC class I molecules in cancer immunosuppression

(2013) Grazyna Kochan et al.   OncoImmunology

Trial Watch

(2013) Erika Vacchelli et al.   OncoImmunology

Proinflammatory Characteristics of SMAC/DIABLO-Induced Cell Death in Antitumor Therapy

(2012) P. U. Emeagi et al.   CANCER RESEARCH

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dendritic Cells for Active Anti-Cancer Immunotherapy: Targeting Activation Pathways Through Genetic Modification

(2012) Karine Breckpot et al.   Endocrine Metabolic & Immune Disorders-Drug Targets

PD-L1 co-stimulation, ligand-induced TCR down-modulation and anti-tumor immunotherapy

(2012) Katarzyna Karwacz et al.   OncoImmunology

Trial watch

(2012) Erika Vacchelli et al.   OncoImmunology

Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors

(2011) F. Aranda et al.   CANCER RESEARCH

PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+T cells

(2011) Katarzyna Karwacz et al.   EMBO Molecular Medicine

The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis

(2011) Catherine E. Steding et al.   IMMUNOLOGY

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors

(2011) Sid P. Kerkar et al.   JOURNAL OF CLINICAL INVESTIGATION

Conventional Dendritic Cells Are Required for the Activation of Helper-Dependent CD8 T Cell Responses to a Model Antigen After Cutaneous Vaccination with Lentiviral Vectors

(2011) H. D. Goold et al.   JOURNAL OF IMMUNOLOGY

A MicroRNA-regulated and GP64-pseudotyped Lentiviral Vector Mediates Stable Expression of FVIII in a Murine Model of Hemophilia A

(2011) Hideto Matsui et al.   MOLECULAR THERAPY

Manipulating Immune Tolerance with Micro-RNA Regulated Gene Therapy

(2011) Kevin Scott Goudy et al.   Frontiers in Microbiology

Lentiviral Vectors in Gene Therapy: Their Current Status and Future Potential

(2010) David Escors et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS

Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis

(2010) Frederick Arce et al.   ARTHRITIS AND RHEUMATISM

Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo

(2010) Cara K. Fraser et al.   CANCER BIOLOGY & THERAPY

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

Blockade of Programmed Death-1 Pathway Rescues the Effector Function of Tumor-Infiltrating T Cells and Enhances the Antitumor Efficacy of Lentivector Immunization

(2010) Q. Zhou et al.   JOURNAL OF IMMUNOLOGY

HIV-1 Lentiviral Vector Immunogenicity Is Mediated by Toll-Like Receptor 3 (TLR3) and TLR7

(2010) K. Breckpot et al.   JOURNAL OF VIROLOGY

Identification of Hematopoietic Stem Cell-Specific miRNAs Enables Gene Therapy of Globoid Cell Leukodystrophy

(2010) B. Gentner et al.   Science Translational Medicine

In vivo delivery of a microRNA-regulated transgene induces antigen-specific regulatory T cells and promotes immunologic tolerance

(2009) A. Annoni et al.   BLOOD

Lentivector Immunization Stimulates Potent CD8 T Cell Responses against Melanoma Self-Antigen Tyrosinase-Related Protein 1 and Generates Antitumor Immunity in Mice

(2009) Yanjun Liu et al.   JOURNAL OF IMMUNOLOGY

Nonintegrating Lentivector Vaccines Stimulate Prolonged T-Cell and Antibody Responses and Are Effective in Tumor Therapy

(2009) K. Karwacz et al.   JOURNAL OF VIROLOGY

Lentiviral Vectors Transduce Proliferating Dendritic Cell Precursors Leading to Persistent Antigen Presentation and Immunization

(2009) Frederick Arce et al.   MOLECULAR THERAPY

Targeting dendritic cell signaling to regulate the response to immunization

(2008) D. Escors et al.   BLOOD

Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity

(2008) K. Movahedi et al.   BLOOD

Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells

(2008) L. Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA